Conjustar

Executive Summary

Conjustar is a Shanghai-based biotechnology company founded in 2020, specializing in next-generation antibody-based cancer therapeutics. The company's pipeline focuses on monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs) designed to improve tumor selectivity and overcome drug resistance in both solid and hematological malignancies. With a lean team of 50-200 employees and no disclosed funding rounds, Conjustar is in Phase 1 development and operates as a private, unlisted entity. The company aims to address key challenges in oncology, including limited efficacy and resistance mechanisms, through precision-targeted approaches. Given its early-stage status and competitive landscape, Conjustar's progress will depend on successful clinical validation and strategic partnerships.

Upcoming Catalysts (preview)

• H2 2027Phase 1 clinical data readout for lead ADC candidate30% success
• Q4 2026IND filing for bispecific antibody program60% success
• Q2 2027Partnership or licensing deal with a major pharma for pipeline assets25% success